- Home
- CSTL vs DGICB Comparison
CSTL vs DGICB Comparison
Compare CSTL & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- DGICB
- Stock Information
- Founded
- CSTL 2007
- DGICB 1986
- Country
- CSTL United States
- DGICB United States
- Employees
- CSTL N/A
- DGICB N/A
- Industry
- CSTL Medical Specialities
- DGICB Property-Casualty Insurers
- Sector
- CSTL Health Care
- DGICB Finance
- Exchange
- CSTL Nasdaq
- DGICB Nasdaq
- Market Cap
- CSTL 471.5M
- DGICB 562.0M
- IPO Year
- CSTL 2019
- DGICB N/A
- Fundamental
- Price
- CSTL $19.36
- DGICB $14.24
- Analyst Decision
- CSTL Strong Buy
- DGICB
- Analyst Count
- CSTL 6
- DGICB 0
- Target Price
- CSTL $37.67
- DGICB N/A
- AVG Volume (30 Days)
- CSTL 554.7K
- DGICB 691.0
- Earning Date
- CSTL 08-04-2025
- DGICB 07-24-2025
- Dividend Yield
- CSTL N/A
- DGICB 4.49%
- EPS Growth
- CSTL N/A
- DGICB 965.80
- EPS
- CSTL N/A
- DGICB 2.34
- Revenue
- CSTL $346,269,000.00
- DGICB $993,644,532.00
- Revenue This Year
- CSTL N/A
- DGICB $2.87
- Revenue Next Year
- CSTL $1.62
- DGICB $4.62
- P/E Ratio
- CSTL N/A
- DGICB $7.27
- Revenue Growth
- CSTL 20.40
- DGICB 3.36
- 52 Week Low
- CSTL $14.59
- DGICB $11.80
- 52 Week High
- CSTL $35.84
- DGICB $20.46
- Technical
- Relative Strength Index (RSI)
- CSTL 58.66
- DGICB 37.61
- Support Level
- CSTL $18.81
- DGICB $14.17
- Resistance Level
- CSTL $21.33
- DGICB $15.11
- Average True Range (ATR)
- CSTL 0.92
- DGICB 0.21
- MACD
- CSTL 0.45
- DGICB -0.05
- Stochastic Oscillator
- CSTL 70.74
- DGICB 17.02
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.